カテゴリー： 世界, 医療/バイオ, MarketsandMarkets

世界の幹細胞療法市場（～2028年）：種類別（同種、自家）、細胞源別（脂肪組織、骨髄、胎盤/臍帯）、治療用途別（筋骨格系、創傷、外科、炎症、自己免疫、心血管）

【英語タイトル】Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Inflammatory, Autoimmune, Cardiovascular) - Global Forecast to 2028

MarketsandMarketsが出版した調査資料（BT5049-24）・商品コード：BT5049-24
・発行会社（調査会社）：MarketsandMarkets
・発行日：2023年12月20日
・ページ数：197
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

“世界の幹細胞療法市場は、2023年の2億8,600万米ドルから2028年には6億1,500万米ドルに達すると予測され、予測期間中の年平均成長率は16.5％”主要な市場関係者は、様々な疾患に対する新しい幹細胞療法の開発に注力しています。ここ数年、幹細胞療法に関する臨床試験の件数が大幅に増加しており、FDA（アメリカ食品医薬品局）による幹細胞療法の承認件数も増加しています。

“2022年には同種幹細胞分野が圧倒的なシェアを占める”
幹細胞療法市場は同種幹細胞と自家幹細胞に区分されます。2022年には同種幹細胞療法が圧倒的なシェアを占めます。同種幹細胞療法では、1つの細胞源から多くの投与量を得ることができるため、同種幹細胞療法は経済的に実行可能であり、時間もかかりません。現在、世界では10種類以上の同種幹細胞療法が承認され、商品化されています。

“骨髄由来MSC分野は大きなCAGRで成長する見込み”
細胞源に基づき、世界の幹細胞療法市場は脂肪組織由来MSC、骨髄由来MSC、胎盤/臍帯由来MSC、その他の細胞源に区分されます。2022年には、脂肪組織由来MSC分野が幹細胞療法市場で圧倒的なシェアを獲得。幹細胞療法に最も好まれる骨髄由来間葉系幹細胞。骨髄由来間葉系幹細胞の入手が容易であること、体外処理に要する時間が短いことなどが、骨髄由来間葉系幹細胞の利用に弾みをつけ、同分野の成長を押し上げる主な要因のひとつ。

“アジア太平洋はより速いペースで成長すると予測”
幹細胞療法市場は、北米、ヨーロッパ、アジア太平洋、その他の地域に区分されます。アジア太平洋は、予測期間中に大きなCAGRで成長すると予測されています。韓国における幹細胞療法に対する政府承認の増加。さらに、同地域における幹細胞療法開発のための産業界との提携は、同地域の市場成長をさらに加速させる可能性があります。例えば、レヨン・ファーマシューティカルとセラベストは、固形がん治療のためのNK細胞療法に関する共同開発契約を締結しました。この合意に基づき、両社は固形がんを適応症とするiPS細胞（人工多能性幹細胞）由来のNK細胞療法「TB-100」を共同開発する予定。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別 供給サイド - 80％、需要サイド - 20％
- 回答者の役職別（供給側） 管理職 - 45％、CXOおよび取締役 - 30％、経営幹部 - 25％
- 地域別 北米 -40％、アジア太平洋 -20％、ヨーロッパ -30％、その他地域-10％

レポート掲載企業一覧は以下の通りです：
- Smith+Nephew (UK)
- MEDIPOST Co. Ltd. (South Korea)
- Anterogen Co. Ltd. (South Korea)
- CORESTEM (South Korea)
- Pharmicell Co. Ltd. (South Korea)
- NuVasive Inc. (US)
- RTI Surgical (US)
- AlloSource (US)
- JCR Pharmaceuticals Co. Ltd. (Japan)
- Takeda Pharmaceutical Company Limited (Japan)
- Holostem Terapie Avanzate Srl (Italy)
- Orthofix (US)
- Regrow Biosciences Pvt Ltd. (India)
- STEMPEUTICS RESEARCH PVT LTD. (India)
- Athersys (US)
- Mesoblast Ltd (Australia)
- Biorestorative Therapies Inc. (US)
- Pluristem Inc. (Israel)
- Brainstorm Cell Limited. (US)
- ViaCyte Inc. (US)
- Gamida Cell (US)
- Kangstem Biotech (South Korea)
- Hope Biosciences (US)
- Cellular Biomedicine Group (US)
- Personalized Stem Cells (US)

調査対象範囲：
本レポートは幹細胞療法市場の詳細な情報を提供します。種類、治療用途、地域などの異なるセグメントにおける市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点：
本レポートは、幹細胞療法市場全体とそのサブセグメントにおける売上高の概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 主要な促進要因（幹細胞研究への資金提供の増加、共同研究やパートナーシップの増加が市場成長を押し上げる可能性が高い、幹細胞を用いた治療の臨床試験の増加）、阻害要因（胚性幹細胞に関連する倫理的懸念、細胞を用いた研究の高コスト）、機会（ESCに代わるiPS細胞の出現、幹細胞および遺伝子治療への需要の増加）、課題（技術的限界）の分析が幹細胞療法市場の成長に影響を及ぼしています。
- 製品開発/イノベーション： 幹細胞療法市場で新たに発売された製品に関する詳細な洞察を記載しています。
- 市場開発： 有利な市場に関する包括的な情報 - 本レポートでは、様々な地域における幹細胞療法市場を分析しています。
- 市場の多様化： 幹細胞療法市場における新規サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- パイプライン分析： 第3相臨床試験中の幹細胞療法に関する詳細情報を提供します。
- 競合評価： Smith+Nephew社（イギリス）、MEDIPOST Co. Ltd.（韓国）、Anterogen Co. (Ltd.（韓国）、Anterogen Co. Ltd.（韓国）、CORESTEM Co. (韓国)、CORESTEM(韓国)などが幹細胞療法市場に参入しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界の幹細胞療法市場規模：細胞源別
7.　世界の幹細胞療法市場規模：種類別
8.　世界の幹細胞療法市場規模：治療用途別
9.　世界の幹細胞療法市場規模：地域別
10.　競争環境
11.　企業情報
12.　付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 INCLUSIONS & EXCLUSIONS 29
1.4 MARKET SCOPE 29
1.4.1 MARKETS COVERED 29
1.4.2 YEARS CONSIDERED 30
1.5 CURRENCY 30
1.6 RESEARCH LIMITATIONS 30
1.7 STAKEHOLDERS 31
1.8 SUMMARY OF CHANGES 31
1.9 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET 35
2.2 MARKET SIZE ESTIMATION 36
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2022 36
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 37
FIGURE 5 SMITH+NEPHEW: REVENUE SHARE ANALYSIS, 2022 37
2.2.1 PRIMARY INSIGHTS 38
FIGURE 6 VALIDATION FROM PRIMARY EXPERTS 38
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: STEM CELL THERAPY MARKET 39
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 39
FIGURE 8 CAGR PROJECTIONS: STEM CELL THERAPY MARKET 40
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 40
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 10 DATA TRIANGULATION METHODOLOGY 41
2.4 STUDY ASSUMPTIONS 42
2.5 RISK ANALYSIS 42
2.6 IMPACT OF RECESSION ON STEM CELL THERAPY MARKET 43
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 43
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 43
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 44
3 EXECUTIVE SUMMARY 45
FIGURE 11 STEM CELL THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 45
FIGURE 12 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 13 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 14 REGIONAL SNAPSHOT OF STEM CELL THERAPY MARKET 47
4 PREMIUM INSIGHTS 49
4.1 STEM CELL THERAPY MARKET OVERVIEW 49
FIGURE 15 INCREASING INVESTMENTS AND FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET 49
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE AND COUNTRY, 2022 50
FIGURE 16 ALLOGENEIC STEM CELL THERAPY ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 50
4.3 STEM CELL THERAPY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 51
FIGURE 17 SOUTH KOREA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Increased funding for stem cell research 53
TABLE 4 FUNDING FOR STEM CELL RESEARCH BY INDIAN COUNCIL OF MEDICAL RESEARCH, 2019–2022 (USD) 53
TABLE 5 FUNDING FOR CELL-BASED RESEARCH BY NATIONAL INSTITUTES OF HEALTH, 2018–2023 (USD MILLION) 53
5.2.1.2 Rising number of collaborations among healthcare institutes 54
5.2.1.3 Increasing number of clinical trials for stem cell-based therapies 55
FIGURE 19 NUMBER OF CLINICAL TRIALS, 2015–2022 55
5.2.2 RESTRAINTS 56
5.2.2.1 Ethical concerns related to use of embryonic stem cells 56
5.2.2.2 High cost of cell-based research and stem cell therapy 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Increased availability of alternatives to embryonic stem cells 57
5.2.3.2 Growing demand for cell and gene therapies 58
5.2.4 CHALLENGES 58
5.2.4.1 Technological limitations 58
5.3 TECHNOLOGY ANALYSIS 59
TABLE 6 COMPARISON BETWEEN STEM CELL THERAPIES AND GENE THERAPIES 59

5.4 DISRUPTIONS AND TRENDS IMPACTING CUSTOMER’S BUSINESS 60
FIGURE 20 REVENUE SHIFT AND NEW POCKET FOR KEY PLAYERS IN STEM CELL THERAPY MARKET 60
5.5 VALUE CHAIN ANALYSIS 60
FIGURE 21 STEM CELL THERAPY MARKET: VALUE CHAIN ANALYSIS 61
5.6 ECOSYSTEM MARKET MAP 61
FIGURE 22 STEM CELL THERAPY MARKET: ECOSYSTEM MARKET MAP 61
5.7 SUPPLY CHAIN ANALYSIS 62
FIGURE 23 STEM CELL THERAPY MARKET: SUPPLY CHAIN ANALYSIS 62
TABLE 7 SUPPLY CHAIN ANALYSIS: ROLE OF COMMERCIAL-SCALE/KEY MANUFACTURERS 63
TABLE 8 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 63
5.8 PORTER’S FIVE FORCES ANALYSIS 64
5.8.1 THREAT OF NEW ENTRANTS 64
5.8.2 THREAT OF SUBSTITUTES 64
5.8.3 BARGAINING POWER OF SUPPLIERS 64
5.8.4 BARGAINING POWER OF BUYERS 65
5.8.5 INTENSITY OF COMPETITION RIVALRY 65
5.9 REGULATORY ANALYSIS 65
5.9.1 REGULATORY LANDSCAPE 65
5.9.1.1 North America 65
TABLE 9 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 65
5.9.1.2 Europe 68
TABLE 10 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 68
5.9.1.3 Asia Pacific 69
TABLE 11 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 69
5.9.1.4 Rest of the World 71
TABLE 12 REST OF THE WORLD: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 71
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.10 PRICING ANALYSIS 75
5.10.1 PRICING ANALYSIS 75
TABLE 17 AVERAGE SELLING PRICE OF DRUG THERAPIES OFFERED BY KEY PLAYERS IN STEM CELL THERAPY MARKET 75
5.10.2 AVERAGE SELLING PRICE TREND FOR STEM CELL THERAPIES 76

5.11 PATENT ANALYSIS 77
FIGURE 24 STEM CELL THERAPY: PATENT ANALYSIS, 2013–2023 77
5.12 KEY CONFERENCES & EVENTS 78
TABLE 18 LIST OF KEY CONFERENCES & EVENTS, 2023–2024 78
5.13 PIPELINE ANALYSIS 78
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 81
FIGURE 25 KEY STAKEHOLDERS 81
5.14.1 KEY BUYING CRITERIA 82
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 82
6 STEM CELL THERAPY MARKET, BY CELL SOURCE 83
6.1 INTRODUCTION 84
TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 84
6.2 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS 84
6.2.1 EASE OF ISOLATION AND HARVESTING TO DRIVE GROWTH 84
TABLE 20 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 21 NORTH AMERICA: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 22 EUROPE: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 23 ASIA PACIFIC: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
6.3 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS 86
6.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH 86
TABLE 24 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 25 NORTH AMERICA: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 26 EUROPE: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 27 ASIA PACIFIC: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.4 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS 88
6.4.1 LOW CHANCES OF REJECTION FROM IMMUNE SYSTEM TO PROPEL GROWTH 88
TABLE 28 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 29 NORTH AMERICA: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 30 EUROPE: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 31 ASIA PACIFIC: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90

6.5 OTHER CELL SOURCES 90
TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 34 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 35 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 92
7 STEM CELL THERAPY MARKET, BY TYPE 93
7.1 INTRODUCTION 94
TABLE 36 STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 94
7.2 ALLOGENEIC STEM CELL THERAPY 94
7.2.1 ECONOMICALLY VIABLE AND LESS TIME-CONSUMING—KEY FACTORS DRIVING MARKET GROWTH 94
TABLE 37 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 38 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 39 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 40 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.3 AUTOLOGOUS STEM CELL THERAPY 96
7.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE GROWTH 96
TABLE 41 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 42 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 43 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 44 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 99
8.1 INTRODUCTION 100
TABLE 45 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 100
8.2 MUSCULOSKELETAL DISORDERS 100
8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE MARKET 100
TABLE 46 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 47 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 48 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 49 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
8.3 WOUNDS & SURGERIES 102
8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH 102
TABLE 50 STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 51 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 52 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 53 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION) 104
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 104
8.4.1 INCREASING CLINICAL TRIALS TO SUPPORT MARKET GROWTH 104
TABLE 54 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 55 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 56 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 57 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 105
8.5 CARDIOVASCULAR DISEASES 106
8.5.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH TO DRIVE MARKET 106
TABLE 58 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 59 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 60 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 61 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 107
8.6 NEUROLOGICAL DISORDERS 107
8.6.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 107
TABLE 62 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 64 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 65 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 109
8.7 OTHER THERAPEUTIC APPLICATIONS 109
TABLE 66 STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 67 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 68 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 69 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 110
9 STEM CELL THERAPY MARKET, BY REGION 111
9.1 INTRODUCTION 112
TABLE 70 STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 112
9.2 NORTH AMERICA 113
FIGURE 27 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 113
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 114
TABLE 73 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 74 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 115
9.2.1 US 115
9.2.1.1 Increase in stem cell therapy approvals to drive market 115
TABLE 75 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 116
TABLE 76 US: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 77 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 116
9.2.2 CANADA 117
9.2.2.1 Increase in research activities targeted toward stem cell therapies to propel market 117
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 117
TABLE 79 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 80 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 118
9.2.3 RECESSION IMPACT ON NORTH AMERICAN STEM CELL THERAPY MARKET 118
9.3 EUROPE 119
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 119
TABLE 83 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 84 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 120
9.3.1 GERMANY 120
9.3.1.1 Increasing incidence of sports-related injuries to drive market 120
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 121
TABLE 86 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 87 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 121
9.3.2 UK 122
9.3.2.1 Rising adoption of cell-based therapies to propel market 122
TABLE 88 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 122
TABLE 89 UK: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 90 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 123
9.3.3 FRANCE 123
9.3.3.1 Rising R&D expenditure for stem cell therapy to support market growth 123
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 124
TABLE 92 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 93 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 124
9.3.4 ITALY 125
9.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market 125
TABLE 94 ITALY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 125
TABLE 95 ITALY: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 96 ITALY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 126
9.3.5 SPAIN 126
9.3.5.1 Rising prevalence of CVD to propel market 126
TABLE 97 SPAIN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 127
TABLE 98 SPAIN: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 99 SPAIN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 127
9.3.6 REST OF EUROPE 128
TABLE 100 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 128
TABLE 101 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 102 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 129
9.3.7 RECESSION IMPACT ON EUROPEAN STEM CELL THERAPY MARKET 129

9.4 ASIA PACIFIC 130
FIGURE 28 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 130
TABLE 103 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 104 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 131
TABLE 105 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 106 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 132
9.4.1 JAPAN 132
9.4.1.1 Growing geriatric population and faster regulatory approval process to augment market growth 132
TABLE 107 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 133
TABLE 108 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 109 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 133
9.4.2 SOUTH KOREA 134
9.4.2.1 Presence of major players to support market growth in South Korea 134
TABLE 110 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 134
TABLE 111 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 112 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 135
9.4.3 INDIA 135
9.4.3.1 Rising incidence of neurodegenerative disorders and diabetes to drive market 135
TABLE 113 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 136
TABLE 114 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 115 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 136
9.4.4 CHINA 137
9.4.4.1 Increasing investments in stem cell research to drive market 137
TABLE 116 CHINA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 137
TABLE 117 CHINA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 118 CHINA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 138
9.4.5 REST OF ASIA PACIFIC 138
TABLE 119 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 138
TABLE 120 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 121 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 139
9.4.6 RECESSION IMPACT ON ASIA PACIFIC STEM CELL THERAPY MARKET 139
9.5 REST OF THE WORLD 140
TABLE 122 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 140
TABLE 123 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 124 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION) 141
9.5.1 RECESSION IMPACT ON REST OF THE WORLD STEM CELL THERAPY MARKET 141
10 COMPETITIVE LANDSCAPE 142
10.1 INTRODUCTION 142
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 143
FIGURE 29 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 143
10.3 REVENUE SHARE ANALYSIS 144
FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS, 2020−2022 (USD MILLION) 144
10.4 MARKET SHARE ANALYSIS 144
FIGURE 31 STEM CELL THERAPY MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 145
TABLE 125 STEM CELL THERAPY MARKET: INTENSITY OF COMPETITIVE RIVALRY 145
10.5 COMPANY EVALUATION MATRIX 146
FIGURE 32 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 147
10.5.1 STARS 147
10.5.2 EMERGING LEADERS 147
10.5.3 PERVASIVE PLAYERS 148
10.5.4 PARTICIPANTS 148
10.6 COMPETITIVE BENCHMARKING OF KEY PLAYERS 148
TABLE 126 THERAPEUTIC APPLICATION FOOTPRINT OF COMPANIES 148
10.7 REGIONAL FOOTPRINT OF TOP 15 COMPANIES 149
TABLE 127 REGIONAL FOOTPRINT OF COMPANIES 149
10.8 STARTUP/SME EVALUATION MATRIX 150
FIGURE 33 STEM CELL THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022 150
10.8.1 PROGRESSIVE COMPANIES 151
10.8.2 RESPONSIVE COMPANIES 151
10.8.3 DYNAMIC COMPANIES 151
10.8.4 STARTING BLOCKS 151
10.9 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 152
TABLE 128 STEM CELL THERAPY MARKET: PRODUCT FOOTPRINT ANALYSIS OF STARTUPS/SMES 152
TABLE 129 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 154
10.10 COMPETITIVE SCENARIOS AND TRENDS 155
10.10.1 PRODUCT APPROVALS 155
TABLE 130 STEM CELL THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020–OCTOBER 2023 155
10.10.2 DEALS 155
TABLE 131 STEM CELL THERAPY MARKET: DEALS, JANUARY 2020–OCTOBER 2023 155
10.10.3 OTHER DEVELOPMENTS 156
TABLE 132 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–OCTOBER 2023 156
11 COMPANY PROFILES 157
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 KEY PLAYERS 157
11.1.1 SMITH+NEPHEW 157
TABLE 133 SMITH+NEPHEW: BUSINESS OVERVIEW 157
FIGURE 34 SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 158
11.1.2 MEDIPOST 160
TABLE 134 MEDIPOST: BUSINESS OVERVIEW 160
FIGURE 35 MEDIPOST: COMPANY SNAPSHOT (2021) 160
11.1.3 JCR PHARMACEUTICALS CO., LTD. 164
TABLE 135 JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW 164
FIGURE 36 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2022) 165
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 167
TABLE 136 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 167
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 168
11.1.5 ANTEROGEN CO., LTD. 170
TABLE 137 ANTEROGEN CO., LTD.: BUSINESS OVERVIEW 170
11.1.6 CORESTEM, INC. 171
TABLE 138 CORESTEM INC.: BUSINESS OVERVIEW 171
FIGURE 38 CORESTEM INC.: COMPANY SNAPSHOT (2021) 171
11.1.7 PHARMICELL CO., LTD 173
TABLE 139 PHARMICELL CO., LTD: BUSINESS OVERVIEW 173
11.1.8 NUVASIVE, INC. 175
TABLE 140 NUVASIVE, INC.: BUSINESS OVERVIEW 175
FIGURE 39 NUVASIVE, INC.: COMPANY SNAPSHOT (2022) 176
11.1.9 RTI SURGICAL 177
TABLE 141 RTI SURGICAL: BUSINESS OVERVIEW 177
11.1.10 ALLOSOURCE 178
TABLE 142 ALLOSOURCE: BUSINESS OVERVIEW 178
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL 179
TABLE 143 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW 179
11.1.12 ORTHOFIX MEDICAL INC. 180
TABLE 144 ORTHOFIX MEDICAL INC.: BUSINESS OVERVIEW 180
FIGURE 40 ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT (2022) 181
11.1.13 STEMPEUTICS RESEARCH PVT LTD. 182
TABLE 145 STEMPEUTICS RESEARCH PVT LTD.: BUSINESS OVERVIEW 182
11.1.14 REGROW BIOSCIENCES PVT LTD. 184
TABLE 146 REGROW BIOSCIENCES PVT LTD.: BUSINESS OVERVIEW 184
11.2 OTHER PLAYERS 185
11.2.1 ATHERSYS, INC. 185
TABLE 147 ATHERSYS, INC.: BUSINESS OVERVIEW 185
11.2.2 MESOBLAST LTD. 186
TABLE 148 MESOBLAST LTD.: BUSINESS OVERVIEW 186
11.2.3 BIORESTORATIVE THERAPIES, INC. 188
TABLE 149 BIORESTORATIVE THERAPIES, INC.: BUSINESS OVERVIEW 188
11.2.4 PLURISTEM THERAPEUTICS INC. 189
TABLE 150 PLURISTEM THERAPEUTICS INC.: BUSINESS OVERVIEW 189
11.2.5 BRAINSTORM CELL LIMITED 190
TABLE 151 BRAINSTORM CELL LIMITED: BUSINESS OVERVIEW 190
11.2.6 GAMIDA CELL 191
TABLE 152 GAMIDA CELL: BUSINESS OVERVIEW 191
11.2.7 VIACYTE, INC. 192
TABLE 153 VIACYTE, INC.: BUSINESS OVERVIEW 192
11.2.8 KANGSTEM BIOTECH CO., LTD. 193
TABLE 154 KANGSTEM BIOTECH CO., LTD.: BUSINESS OVERVIEW 193
11.2.9 HOPE BIOSCIENCES 194
TABLE 155 HOPE BIOSCIENCES: BUSINESS OVERVIEW 194
11.2.10 CELLULAR BIOMEDICINE GROUP 195
TABLE 156 CELLULAR BIOMEDICINE GROUP: BUSINESS OVERVIEW 195
11.2.11 PERSONALIZED STEM CELLS 196
TABLE 157 PERSONALIZED STEM CELLS: BUSINESS OVERVIEW 196
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 197
12.1 DISCUSSION GUIDE 197
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 200
12.3 CUSTOMIZATION OPTIONS 201
12.4 RELATED REPORTS 202
12.5 AUTHOR DETAILS 203



★調査レポート[世界の幹細胞療法市場（～2028年）：種類別（同種、自家）、細胞源別（脂肪組織、骨髄、胎盤/臍帯）、治療用途別（筋骨格系、創傷、外科、炎症、自己免疫、心血管）] (コード：BT5049-24)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の幹細胞療法市場（～2028年）：種類別（同種、自家）、細胞源別（脂肪組織、骨髄、胎盤/臍帯）、治療用途別（筋骨格系、創傷、外科、炎症、自己免疫、心血管）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の再生医療市場（～2028年）：製品別（幹細胞（自己由来、同種異系）、免疫療法、遺伝子療法、ティッシュエンジニアリング）、用途別（筋骨格系、がん、皮膚科、創傷治療、心血管疾患、眼疾患）
  • 細胞単離/細胞分離の世界市場予測（～2028年）：製品別、細胞別、細胞源別、技術別、用途別、エンドユーザー別
  • 世界の抗体治療薬市場（～2028年）：フォーマット別（モノクローナル、ポリクローナル、抗体フラグメント、二重特異性）、疾患領域別（腫瘍学、自己免疫・炎症性、神経学、血液学、感染症）、ソース別（ヒト、キメラ）、経路別（IV、SC）
  • 世界の空カプセル市場（～2028年）：種類別（ゼラチン、非ゼラチン）、機能別（即時放出、持続放出、遅延放出）、治療用途別、エンドユーザー別（医薬品、栄養補助食品、化粧品、リファレンスラボラトリー）、地域別
  • 世界の間葉系幹細胞市場2022ｰ2032：コンポーネント別（製品（ワークフロータイプ、製品タイプ）、サービス）、種類別（自己、同種異系）、分離元別（骨髄、臍帯血、末梢血、卵管、胎児肝、肺、脂肪組織）、疾患別（骨・軟骨修復、循環器疾患、炎症・免疫疾患、肝疾患、癌、GvHD、その他）、地域別
  • 世界の再生医学(医療)市場2024-2030：製品別（一次細胞系治療薬、幹細胞・前駆細胞系治療薬）、治療カテゴリー別（皮膚科、筋骨格系）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆